Maguran (Doxazosin)

Doxazosin selectively blocks alpha‑1 adrenergic receptors on vascular smooth muscle and in the prostate. This inhibition prevents norepinephrine‑mediated contraction, leading to vasodilation, lower peripheral resistance, and reduced blood pressure, while also relaxing prostatic and bladder neck muscles to improve urine flow.

The specific dose of Maguran is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for doxazosin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Maguran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with non‑selective alpha blockers, doxazosin offers more targeted alpha‑1 blockade, resulting in fewer reflex tachycardia effects. It is often chosen for patients who need both blood pressure control and relief of BPH symptoms, whereas other classes like ACE inhibitors or calcium channel blockers do not address urinary obstruction.

Maguran should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Maguran is taken orally, usually once daily, with or without food as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe hypotension, syncope, and rare events such as priapism, angioedema, or significant liver injury. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, prolonged erection, swelling of the face or throat, or signs of liver dysfunction.

Maguran is contraindicated in patients with known hypersensitivity to doxazosin or any component of the formulation, and in individuals with severe hypotension or a history of orthostatic collapse. Caution is also advised for patients with significant liver disease or those taking interacting medications without proper monitoring.